论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Hao Y, Bai X, Liu X, Kang S, Zhang X, Liu C, Li Z
Received 10 January 2018
Accepted for publication 9 June 2018
Published 17 April 2019 Volume 2019:12 Pages 2921—2930
DOI https://doi.org/10.2147/OTT.S162150
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Manfred Beleut
Peer reviewer comments 3
Editor who approved publication: Dr XuYu Yang
Background: Survivin,
a member of the inhibitor of apoptosis protein family, is highly expressed in
many cancers and has important roles in inhibiting apoptosis by blocking
caspase activation. However, its antitumor effects remain largely unknown. Here
we explore the function of survivin in skin cancer.
Methods: We used
qPCR and Western blot to examine survivin expression in skin cancer patients
and cell line. We generated several survivin shRNA constructs and tested the
effects of survivin shRNA on cancer cell viability using MTT assay, flow
cytometry, and TUNEL assay.
Results: We found
that survivin was upregulated in both skin cancer patients and skin cancer cell
line A431. Knockdown survivin via shRNA inhibited cancer cell proliferation and
promoted apoptosis in both A431 cell and in vivo xenograft tumor mouse model.
The antitumor effect is comparable to resveratrol, a drug known to inhibit
cancer progression. Moreover, we showed that inhibition of survivin was able to
increase the expression of cleaved caspase 7/caspase 9 and activate the
ataxia-telangiectasia mutated-NF-κB pathway in A431 cells.
Conclusion: Survivin-shRNA
possesses antitumor abilities in vitro and in vivo by inhibiting the
proliferation and promoting apoptosis of A431 cells. It may serve as a
potential anticancer target for skin cancer therapy in the future.
Keywords: survivin,
skin cancer, apoptosis, NF-κB, caspases 7/9